Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation

• Status: Not yet recruiting
• Trial end date: 2024-12-15
• Target enrollment: 0
• Participant gender: All

Summary

the aim of the study is to approve the hypothesis that dexmedetomidine can protect against glycocalyx degradation induced by hepatic ischemia-reperfusion injury and hence can reduce the subsequent complications as early allograft dysfunction, other organ dysfunction and hemodynamic instability

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

1. Patients aged 18-60 years.

2. Model for end-stage liver disease (MELD) score 12-20.

3. No severe hemodynamic instability.

4. The liver donors aged 18-50 years and the sum of macro- and microvesicular hepatic steatosis has to be less than 30%.

Exclusion Criteria:

1. History of psychiatric/neurological illness.

2. Cardiovascular disease.

3. Hypertensive patients.

4. Morbid obese patients (body mass index (BMI) > 35).

5. Chronic obstructive pulmonary disease; pulmonary dysfunction (PaO2 less than 60 mmHg).

6. Known allergic reaction to any of the study medications.